HGH vs Teriparatide
FDA Approved vs Extensively Studied
synergistic Mechanism-based · 55% HGH and Teriparatide work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
HGH Teriparatide
Weight 22,124 Da 4,118 Da
Half-life 3-4 hours (SC), 20-30 minutes (IV) ~1 hour (subcutaneous); ~5 minutes (intravenous)
Chain 191 amino acids 34 amino acids
Type Single-chain polypeptide with two disulfide bridges Recombinant PTH fragment
Key Benefits
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
Teriparatide
01 FDA-approved for osteoporosis treatment
02 Actively builds new bone (anabolic)
03 Increases spine bone density by 5-9%
04 Reduces vertebral fracture risk by 65%
05 Reduces nonvertebral fractures by 35%
06 Works differently than antiresorptive drugs
07 Benefits seen within 3 months
08 Creates 'anabolic window' for bone growth
Dosing Protocols
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
Teriparatide
20mcg daily (FDA-approved dose) / Once daily at same time each day
Osteoporosis treatment 20 mcg Once daily
Side Effects
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
Teriparatide
Injection site reactions
Nausea
Headache
Leg cramps
Dizziness
Joint pain
Contraindications
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Paget's disease of bone
Prior skeletal radiation therapy
History of skeletal malignancies
Metabolic bone diseases other than osteoporosis
Pre-existing hypercalcemia
Pregnancy
Research Evidence
HGH Teriparatide
Status FDA Approved Extensively Studied
References 4 studies 4 studies
Latest 2024 —
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.